Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Inclusion Criteria

• •Age :18 Years to 75 Years;
• •ECOG physical score 0-2 points; expected survival time ≥ 1 year;
• •Pathologically confirmed diagnosis with Stage III NSCLC which harbored ALK fusion detected by next generation sequencing (NGS) or immunohistochemistry (IHC) with or without FISH. Suspected N2 (station 2/4/7) for stage III disease should be confirmed by either mediastinoscopy or EBUS.
• •At least one measurable target lesion according to the RECIST 1.1 standard;
• •The main organ function meets the following criteria: 1) blood routine: absolute value of neutrophils ≥ 1.5 × 109 / L, platelets ≥ 75 × 109 / L, hemoglobin ≥ 80 g / L; 2) blood biochemistry: total bilirubin ≤ 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal value (if liver metastasis, ≤ upper limit of normal value 5 times), serum creatinine ≤ 1.5 times the upper limit of normal;
• •Subjects voluntarily joined the study and signed informed consent, with good compliance to follow-up.